IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials DOI Creative Commons
Jihan K. Zaki, Jakub Tomasik,

Sabine Bahn

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107633 - 107633

Published: Jan. 1, 2025

There is an urgent need for mechanistically novel and more efficacious treatments schizophrenia, especially those targeting negative cognitive symptoms with a favorable side-effect profile. Drug repurposing-the process of identifying new therapeutic uses already approved compounds-offers promising approach to overcoming the lengthy, costly, high-risk traditional CNS drug discovery. This review aims update our previous findings on clinical repurposing pipeline in schizophrenia. We examined studies conducted between 2018 2024, 61 trials evaluating 40 unique repurposed candidates. These encompassed broad range pharmacological mechanisms, including immunomodulation, enhancement, hormonal, metabolic, neurotransmitter modulation. A notable development combination muscarinic modulators xanomeline, compound antipsychotic properties, trospium, included mitigate peripheral side effects, now by FDA as first decades fundamentally mechanism action. Moving beyond dopaminergic paradigm such highlight opportunities improve treatment-resistant alleviate adverse effects. Overall, evolving landscape illustrates significant shift rationale schizophrenia development, highlighting potential silico strategies, biomarker-based patient stratification, personalized that align underlying pathophysiological processes.

Language: Английский

Circular reasoning concerning Red flags for predicting rituximab response in OCD DOI Creative Commons
Susanne Bejerot,

A. Hietala,

Annika Söderbergh

et al.

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Language: Английский

Citations

0
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials DOI Creative Commons
Jihan K. Zaki, Jakub Tomasik,

Sabine Bahn

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107633 - 107633

Published: Jan. 1, 2025

There is an urgent need for mechanistically novel and more efficacious treatments schizophrenia, especially those targeting negative cognitive symptoms with a favorable side-effect profile. Drug repurposing-the process of identifying new therapeutic uses already approved compounds-offers promising approach to overcoming the lengthy, costly, high-risk traditional CNS drug discovery. This review aims update our previous findings on clinical repurposing pipeline in schizophrenia. We examined studies conducted between 2018 2024, 61 trials evaluating 40 unique repurposed candidates. These encompassed broad range pharmacological mechanisms, including immunomodulation, enhancement, hormonal, metabolic, neurotransmitter modulation. A notable development combination muscarinic modulators xanomeline, compound antipsychotic properties, trospium, included mitigate peripheral side effects, now by FDA as first decades fundamentally mechanism action. Moving beyond dopaminergic paradigm such highlight opportunities improve treatment-resistant alleviate adverse effects. Overall, evolving landscape illustrates significant shift rationale schizophrenia development, highlighting potential silico strategies, biomarker-based patient stratification, personalized that align underlying pathophysiological processes.

Language: Английский

Citations

0